CLPT

ClearPoint Neuro, Inc.

NasdaqAdd to watchlist

Healthcare · Medical Devices

$13.83

+$0.09+0.66%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

7 of 9 open-market sales on file ran under a pre-arranged trading plan ($2.93M), 2 did not. Who, and when

Aug 24, 2026$13.83

−$1.34−8.83%over 1M

Session

Day range74% of range

$13.57$13.92

Fundamentals

Visualize fundamentals and more

Market cap: 417.2M
P/E ratio: -

Revenue grew +17.78% in FY2025, +8.91% faster than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AMar 2026 10-KFeb 2025

added: 112
dropped: 41
re-drafted: 21

Out of 272 passages in this year’s Item 1A.

New this year

Any investment in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below and all information contained in this Annual Report before you decide whether to purchase our common stock. If any of …

152 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Product recalls
Litigation
Cybersecurity
Data privacy
Debt covenants
Dilution

And 17 more.

FDA approval
Regulatory agencies, including the FDA, may impose more stringent 21 Table of Contents requirements on these novel therapies, and the evolving regulatory landscape may create additional hurdles, including longer review times, requests for additional data, or …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Aug 3 Results announcement Company filing 8-K
Aug 3 Quarterly report Company filing 10-Q
Jun 29 BURNETT JOSEPH sold 20,000 shares Insider trading Form 4 CEO and President, about $388k, planned (10b5-1)

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

ClearPoint Neuro, Inc. investor relations

What CLPT has filed with the SEC. This is not ClearPoint Neuro, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like ClearPoint Neuro, Inc.

Also filed under Medical Devices, ranked by how closely they sit beside CLPT.

BSXBoston Scientific Corp.compare with CLPT
MDTMedtronic plccompare with CLPT
ABTAbbott Laboratories

EWEdwards Lifesciences Corpcompare with CLPT

Ask about ClearPoint Neuro, Inc.

The assistant answers from what CLPT has actually filed: 16 annual reports filed with the SEC, 75 Form 4 filings from the last year and 2 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from CLPT's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of ClearPoint Neuro, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with ClearPoint Neuro, Inc.

Be told the moment a CLPT insider trades
Put ClearPoint Neuro, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
ClearPoint Neuro, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about ClearPoint Neuro, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Recent activity

Aug 3 Results announcement Company filing 8-K
Aug 3 Quarterly report Company filing 10-Q
Jun 29 BURNETT JOSEPH sold 20,000 shares Insider trading Form 4 CEO and President, about $388k, planned (10b5-1)

17 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KFeb 2025

added: 112
dropped: 41
re-drafted: 21

Out of 272 passages in this year’s Item 1A.

New this year

Any investment in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below and all information contained in this Annual Report before you decide whether to purchase our common stock. If any of …

152 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Product recalls
Litigation
Cybersecurity
Data privacy
Debt covenants
Dilution

And 17 more.

FDA approval
Regulatory agencies, including the FDA, may impose more stringent 21 Table of Contents requirements on these novel therapies, and the evolving regulatory landscape may create additional hurdles, including longer review times, requests for additional data, or …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add